Abstract
Final Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome after Failure of Hypomethylating Agent Therapy
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have